<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676949</url>
  </required_header>
  <id_info>
    <org_study_id>KU-CY5peptides</org_study_id>
    <secondary_id>19-40</secondary_id>
    <nct_id>NCT00676949</nct_id>
  </id_info>
  <brief_title>Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors</brief_title>
  <acronym>peptidevac</acronym>
  <official_title>Phase I Study of Tumor Specific Potentiated Vaccine Therapy Using Cyclophosphamide Combined Epitope Peptide Cocktail for Progressive/Relapsed Solid Tumors(GI/Lung/Cervical Cancer)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyushu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyushu University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical safety and efficacies of
      cyclophosphamide combined cancer specific epitope peptides cocktail for advanced/relapsed
      solid tumors including GI/lung/cervical cancers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      KOC1, TTK, CO16(URLC10), DEPDC1, MPHOSPH1 have been identified using genome-wide expression
      profile analysis by the use of cDNA microarray in the previous studies. The investigators
      have determined the HLA-A*2402 restricted epitope peptides respectively derived from KOC1,
      TTK, CO16(URLC10), DEPDC1, and MPHOSPH1 showed strong INF-gamma production when stimulated
      with the appropriate targets expressing the appropriate protein and HLA-A*2402. Furthermore,
      when vaccinated these peptides, specific CTLs were determined after the vaccination.
      Therefore the investigators focused on the prevention of further expansion of the solid
      tumors highly expressing these 5 proteins using these 5 peptides.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety of the cyclophosphamide combined tumor specific epitope peptide cocktail</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>immunological efficacies and clinical efficacies of the cyclophosphamide combined tumor specific epitope peptides cocktail</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Metastatic Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cyclophosphamide dose escalation, level 1:150mg/m2,level 2: 300mg/m2, level 3: 300mg/m2x2, with 5 kinds o tumor specific antigen peptides followed by low dose IL-2, 6 patients will be enrolled for each level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1</intervention_name>
    <description>1mg each of 5 peptides with IFA. 4 weekly s.c. administration.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>5 peptide cocktail</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of unresectable or relapsed gastrointestinal, lung or cervical
             cancer patients

          -  performance status 0-1

          -  age between 20 and 80

          -  at least 4 weeks after previous therapy

          -  life expectancy more than 3 months

          -  permissible bone marrow, liver and renal function

          -  HLA-A2402

          -  no viral hepatitis, HIV or HTLV1

        Exclusion Criteria:

          -  severe underlying disease

          -  pregnant or lactating women

          -  active brain metastasis

          -  uncontrollable infection

          -  under systemic corticosteroid or immune suppressant treatment

          -  history of allergy to epitope peptides or IFA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenzaburo Tani, MD,phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Institute of Bioregulation, Kyushu University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.bioreg.kyushu-u.ac.jp/labo/mcg/</url>
    <description>Department of Advanced Molecular and Cell Therapy</description>
  </link>
  <reference>
    <citation>Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46.</citation>
    <PMID>15930316</PMID>
  </reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Department of Advanced Molecular and Cell Therapy</name_title>
    <organization>Kyushu University</organization>
  </responsible_party>
  <keyword>epitope peptide</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>interleukin-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

